Compare SCI & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCI | ABVX |
|---|---|---|
| Founded | 1962 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 9.6B |
| IPO Year | N/A | N/A |
| Metric | SCI | ABVX |
|---|---|---|
| Price | $76.74 | $130.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $92.00 | ★ $112.83 |
| AVG Volume (30 Days) | 832.8K | ★ 1.5M |
| Earning Date | 10-29-2025 | 08-11-2025 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ 8.17 | N/A |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $4,290,729,999.00 | $7,073,400.00 |
| Revenue This Year | $4.08 | $6.80 |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | $20.80 | ★ N/A |
| Revenue Growth | ★ 3.41 | N/A |
| 52 Week Low | $71.75 | $4.77 |
| 52 Week High | $86.83 | $130.25 |
| Indicator | SCI | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 68.06 |
| Support Level | $75.34 | $107.06 |
| Resistance Level | $78.81 | $130.25 |
| Average True Range (ATR) | 1.51 | 7.01 |
| MACD | -0.11 | -0.23 |
| Stochastic Oscillator | 28.90 | 74.57 |
Service Corp International is a personal services company that provides funeral and cemetery services and products from its locations throughout the United States and Canada. The company segments its operations into funeral service and cemetery business functions. At its funeral service locations, Service Corp. provides all professional services, facilities, vehicles, and merchandise related to funerals and cremations. Cemetery locations provide cemetery property, memorial markers, and graveyard services to customers. Service Corp. derives the majority of its revenue from its funeral services segment. Geographically, the company derives a majority of its revenue from the United States.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.